Holland, Thomas L.
Baddour, Larry M.
Bayer, Arnold S.
Hoen, Bruno
Miro, Jose M.
Fowler, Vance G. Jr
Article History
First Online: 1 September 2016
Competing interests
: V.G.F. reports the following potential conflicts of interest: Chair of the Scientific Advisory Board for Merck V710 <i>Staphylococcus aureus</i> vaccine; paid consultant for Pfizer, Novartis, Galderma, Novadigm, Durata, Debiopharm, Genentech, Achaogen, Affinium, Medicines Co., Cerexa, Tetraphase, Trius, MedImmune, Bayer, Theravance, Cubist, Basilea, Affinergy, Arsanis and XBiotech; grants pending from MedImmune, Actavis/Forest/Cerexa, Pfizer, Merck/Cubist, Advanced Liquid Logics, Theravance, Novartis, Contrafect, Genentech and Karius; royalties from UpToDate; personal fees for the development or presentation of educational presentations from Green Cross, Cubist, Cerexa, Durata and Theravance; and a patent pending related to sepsis diagnostics. T.L.H. reports the following potential conflicts of interest: paid consultant for The Medicines Company and Basilea Pharmaceutica; and royalties from UpToDate. A.S.B. reports the following potential conflicts of interest: research grants from ContraFect and Theravance; and advisory board member for ContraFect. J.M.M. reports the following potential conflicts of interest: consulting honoraria and/or research grants from AbbVie, Bristol-Myers Squibb, Cubist, Genentech, Merck, Novartis, Gilead Sciences, ViiV Healthcare and Instituto de Salud Carlos III, Ministerio de EconomÃa y Competitividad, Madrid (Spain)a personal intensification research grant #INT15/00168 during 2016. L.M.B. and B.H. declare no conflicts of interest.
Free to read: This content has been made available to all.